Founded in 2012 as a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments.
Fully reporting and trades publicly under the symbol: RGBP
Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing
Currently 2 Investigational New Drug applications (IND) filed with the FDA
Three products in preclinical development based on the newly discovered cancer stem cell gene target
INVESTOR RELATIONS | REGEN BIOPHARMA, INC.
Regen BioPharma Inc. trades under the symbol RGBP on the OTC Bulletin Board and OTC PINK markets. Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. Currently the Company is focused on developing treatments for aplastic anemia, gene silencing therapy for treating cancer, telomeres and small molecule therapies.
For regulatory filings by the company, click here.
Visit us on Twitter
Regen BioPharma :: Fast Forwarding Stem Cell Medicine
Copyright Regen BioPharma, Inc. 2015